GliaPharm SA’s Post

In a recent investor webinar, our Executive Director, Dr. Thomas Duthy, shared exciting updates on our progress in developing a treatment for #RettSyndrome. Dr Duthy highlighted the success of our Phase I/II clinical trial (NTIRTT1) using NTI164, a broad-spectrum cannabinoid drug therapy. The trial demonstrated significant clinical benefits and safety in girls with Rett Syndrome. Dr Duthy expressed his pride in $NTI's achievements, stating, "The company has delivered in spades. We have had three clinical trials in PANDAS, PANS, Autism and now Retts Syndrome. All basically deliver results and we're very proud of that." #Neurotech #NTI #RettSyndrome #ClinicalTrial #Neuroscience #biotech #smallcaps #smallcapstocks #biotechnology #investors #PANDAS #PANS #autism

iPSC and Cardiac Disease Scientists Q.) How do you take adolescent looking cardiomyocytes to adult looking cardiomyocytes? A.) Collaborate and invest time, energy and focus on the MATURATION MEDIA See the post attached to learn more about “Evaluation of a new media designed to drive improved maturity of iPSC-derived cardiomyocytes for cardiac disease, cardiotoxicity and drug screening". #MEA #cellculture #ISSCR #cardiacdisease #MPS #organoids #organonchip #biotech #pharma

Tucson Biotech Bike Ride #6 took place on Saturday, March 30th with Zachary S. Brooks, PhD, EMBA from UGenome AI and Nicholas King from Critical Path Institute (C-Path). The next Tucson Biotech Bike Ride will take place on Saturday, April 28th starting at 7am. #ThisIsTucson, #techlauncharizona, #ugenomeai, #theracea, #metfora, #bioinformatics , #biotech, #genetics, #science, #medicine, #drugdiscovery, #radiopharmaceuticals, #lifesciences, #health, #pharma, #bloodtesting, #CPath, #CPAD, #CPP, #NSAM, #neuroscience, #globalhealth, #alzheimers, #parkinsons, #drugdevelopment, #datasharing, #collaboration, #clinicaltrials, #FDA, #EMA

At Johnson & Johnson Innovative Medicine, we’re constantly seeking new ways to be on the cutting edge of #drugdiscovery. On the heels of a recent collaboration to advance the discovery and optimization of small molecule medicines, we’re entering into another new collaboration with BigHat Biosciences for strategic antibody discovery and design in #neuroscience.   Why is this so game-changing? This collaboration will combine our expertise in drug discovery, clinical development and #datascience with BigHat’s #machinelearning technologies that are integrated with a high-speed wet lab to accelerate the design of therapeutic proteins with more complex functions and better biophysical properties – with the ultimate goal of bringing novel innovations in neuroscience to patients around the world faster and more efficiently.   The team at J&J is looking forward to integrating this collaboration into our efforts to lead where medicine is going. Shout out to our amazing teams that has made this effort possible, including Mark DePristo, Elizabeth Schwarzbach, Peyton Greenside, and the team at BigHat, as well as the amazing cross-functional team at J&J across #DataScience & #DigitalHealth, #Discovery, #Neuroscience and J&J #Innovation, including David Apfel, Michael Bemben, PhD, Julian Bertschinger, Elena Diez Cecilia, PhD, MBA, Andrea Houghton, Ekaterine (Eka) Kortkhonjia, Sarah Lively, Tommaso Mansi, Bill Martin, PhD, Emma R Parmee, Justin Scheer, Richard Tillyer, Gayle Wittenberg, Ph.D. and many more. Learn more about this collaboration: https://bit.ly/3Whk04X

At Neuroservices-Alliance, we provide advanced cell and slice-based electrophysiology assays to explore the intrinsic excitability of neurons, which is key to understanding epilepsy and supporting the development of antiepileptic drugs (AEDs). Our solutions, including whole-cell patch-clamp and brain slice recordings, offer a comprehensive analysis of neuronal behavior by measuring: 🔹 Resting membrane potential 🔹 Input resistance 🔹 Action potential firing 🔹 Afterhyperpolarization (AHP) 🔹 Synaptic currents (EPSCs/IPSCs) 🔹 … By focusing on these parameters, we help uncover critical insights into neuronal hyperexcitability, ensuring you have the data you need to drive epilepsy drug discovery forward. Interested in learning more about our capabilities? #AskUsAtSfN booth 459! 🗓️ Book a meeting with us during #Neuroscience2024: https://lnkd.in/eEkM9xDN #Epilepsy #IntrinsicExcitability #Electrophysiology #DrugDevelopment #NeuroservicesAlliance #AEDs #PharmaResearch

Alzheimer's disease is a global concern, with rising costs and an urgent need for effective treatments. Dr. Geerts, Hugo, Head of Neuroscience Applied Biosimulation at Certara, recently addressed these challenges and advancements in Alzheimer's research at the University of Indiana. In his presentation on "The Neuroplatform," Dr. Geerts emphasized the importance of a comprehensive approach. Gain insights into our advanced QSP model and its pivotal role in predicting drug efficacy for potential disease-modifying treatments. Watch the presentation here: https://ow.ly/Iph450Rr59A #Alzheimers #Research #DrugDiscovery #Neuroscience #Biosimulation #Certara #Innovation

Are you attending the International Congress of Parkinson's Disease and Movement Disorders from September 27 - October 1? If so, don't miss our poster titled "The Effect of Modulating Alpha-synuclein Aggregation on Clinical Outcome in the Presence of Standard-of-care Dopaminergic Therapy in Parkinson’s Disease. A Quantitative Systems Pharmacology Approach," presented by Hugo Geerts, Head of QSP Neurosciences. We are happy to discuss how we can support your Parkinson's Disease and Movement Disorders programs with biosimulation. For more information visit: https://lnkd.in/dbbMmRAS #MDSCongress #ParkinsonsDisease #MovementDisorders #DrugDevelopment #QuantitativeSystemsPharmacology

Kariya is pleased to announce the successful dosing of the first cohort in a Phase 1 clinical trial of KP405, a novel, brain-penetrant, dual incretin (GLP-1/GIP) receptor agonist for the treatment of Parkinson’s Disease. The single center Phase I study is a first-in-human, randomized, placebo-controlled, clinical trial conducted by strategic partner MAC Clinical Research in Manchester, UK. The two-part study will evaluate the safety, tolerability, pharmacokinetics (PK), and potential pharmacodynamic (PD) effect of both single ascending doses (SAD) and multiple ascending doses (MAD) of subcutaneously administered KP405 in healthy subjects and Parkinson’s patients. #PhaseI #firstinhuman #clinicaldevelopment #endparkinsonsdisease #cureparkinsonsdisease #parkinsonsresearch #parkinsonsdisease #movementdisorders #patientsarewaiting #hope #BioInnovationInstitute #DKlifescience #DKBiotek #neuroscience #CNS #onestepcloser 

🔬Citation Break!📖 This citation studies the relationship between endogenous Alpha-Synuclein expression and neuronal cell death. Our Alpha-Synuclein (cat# S-1001) was used to generate fibrils for further experimentation. rPeptide offers an array of Synuclein monomers, as well as preformed Alpha-Synuclein Fibrils (cat# ASF-1001) for those wishing to avoid the time consuming and costly fibrillization processes. Paper: https://t.ly/Q4TDv Alpha-Synuclein: https://t.ly/aLInt #Research #Development #Experiment #Alpha #Synuclein

TALK ALERT! We are at the 12th Alzheimer’s & Parkinson’s Drug Development Summit today. If you are there, make sure to attend the talk by Neil Matharoo, bit․bio at 11 am. If you’re not attending the summit, don’t worry. You can learn more about our AD/PD disease model cells here: https://hubs.ly/Q02tYb1d0 #research #DrugDiscovery #science #neuroscience #data #talk #CRISPR #optiox #ioCells #ioDiseaseModelCells #ioCRISPRReadyCells #ioMotorNeurons #Microglia #ioGlutamateticNeurons #HTS #Conference